Pub. Date : 2020 Mar
PMID : 31756496
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. | crizotinib | ALK receptor tyrosine kinase | Homo sapiens |
| 2 | INTRODUCTION: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). | crizotinib | ALK receptor tyrosine kinase | Homo sapiens |
| 3 | INTRODUCTION: We report updated data from a phase 2 randomized study evaluating brigatinib in crizotinib-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). | crizotinib | ALK receptor tyrosine kinase | Homo sapiens |